Bank of New York Mellon Corp Purchases 9,888 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Bank of New York Mellon Corp lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 2.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 421,938 shares of the company's stock after acquiring an additional 9,888 shares during the period. Bank of New York Mellon Corp owned 0.34% of Vaxcyte worth $34,540,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of PCVX. Amalgamated Bank boosted its position in shares of Vaxcyte by 8.6% during the 3rd quarter. Amalgamated Bank now owns 4,081 shares of the company's stock worth $466,000 after purchasing an additional 322 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Vaxcyte by 186.2% in the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock worth $6,022,000 after acquiring an additional 34,287 shares in the last quarter. Atria Investments Inc acquired a new stake in Vaxcyte in the third quarter valued at approximately $286,000. TimesSquare Capital Management LLC bought a new stake in shares of Vaxcyte during the third quarter valued at approximately $30,752,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Vaxcyte during the third quarter valued at approximately $1,016,000. 96.78% of the stock is owned by institutional investors.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total transaction of $710,240.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,720,610.98. This represents a 6.81 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the business's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 54,250 shares of company stock worth $4,550,258 over the last three months. 3.10% of the stock is currently owned by insiders.

Remove Ads

Analysts Set New Price Targets

PCVX has been the subject of several research reports. Needham & Company LLC reissued a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. Guggenheim reiterated a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a "buy" rating and a $135.00 target price on the stock. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $147.50.

Vaxcyte Trading Up 1.4 %

Shares of PCVX traded up $0.96 on Tuesday, reaching $69.85. 971,617 shares of the company's stock traded hands, compared to its average volume of 1,189,999. The stock's 50 day simple moving average is $83.06 and its two-hundred day simple moving average is $94.66. The stock has a market cap of $8.99 billion, a PE ratio of -15.18 and a beta of 1.02. Vaxcyte, Inc. has a 52-week low of $58.10 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. Analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.